This unanticipated result indicated that the antitumor activity of MAZ51 in gliomas is likely to be independent of its inhibition of VEGFR-3 phosphorylation, although the precise mechanism remains to be determined. The gene discussed is FLT4; the disease is central nervous system cancer.